Ambalal Sarabhai Enterprises Ltd

₹ 34.1 -1.62%

09 Jun - close price

About

Incorporated in 1977, Ambalal Sarabhai Enterprises Ltd is in the business of manufacturing Pharmaceuticals and Electronics^[1]

Key Points

Business Overview:^[1]
ASE is a pharmaceutical health care companies, which through its group companies, manufactures and markets pharmaceutical, molecular diagnostics, and electronics products in India and abroad

Website BSE NSE

Market Cap ₹ 264 Cr.
Current Price ₹ 34.1
High / Low ₹ 38.8 / 23.1
Stock P/E 14.2
Book Value ₹ 20.7
Dividend Yield 0.00 %
ROCE 11.5 %
ROE 12.4 %
Face Value ₹ 10.0

Add ratio to table

Edit ratios

Pros

Cons

Though the company is reporting repeated profits, it is not paying out dividend
The company has delivered a poor sales growth of 4.37% over past five years.
Promoter holding is low: 31.4%
Tax rate seems low
Company has a low return on equity of 7.81% over last 3 years.
Earnings include an other income of Rs.14.8 Cr.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Edit Columns

Loading peers table ...

Detailed Comparison with:

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
	44.44	36.10	40.01	43.11	54.35	40.70	44.70	45.97	64.81	40.34	44.45	52.00	65.49
	41.09	40.07	39.00	40.58	49.70	40.23	42.16	46.67	59.51	38.88	44.09	47.92	59.79
Operating Profit	3.35	-3.97	1.01	2.53	4.65	0.47	2.54	-0.70	5.30	1.46	0.36	4.08	5.70
OPM %	7.54%	-11.00%	2.52%	5.87%	8.56%	1.15%	5.68%	-1.52%	8.18%	3.62%	0.81%	7.85%	8.70%
	5.71	1.37	2.85	1.63	4.79	2.30	2.80	5.76	-5.37	8.36	1.62	1.94	3.02
Interest	0.99	0.95	0.92	0.99	0.90	0.95	1.22	1.14	0.96	1.01	0.96	0.70	1.42
Depreciation	0.92	1.05	1.14	1.13	0.25	0.98	1.01	0.99	1.02	0.88	1.06	0.96	1.05
Profit before tax	7.15	-4.60	1.80	2.04	8.29	0.84	3.11	2.93	-2.05	7.93	-0.04	4.36	6.25
Tax %	20.14%	5.87%	40.00%	34.31%	-8.69%	59.52%	15.76%	23.89%	-86.83%	-3.66%	1,300.00%	16.51%	-4.00%
	5.71	-4.87	1.08	1.33	9.02	0.35	2.62	2.23	-0.27	8.22	-0.56	3.64	6.50
EPS in Rs	0.75	-0.64	0.14	0.17	1.18	0.05	0.34	0.29	-0.04	1.07	-0.07	0.47	0.85
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	124	132	134	125	150	133	163	197	170	173	196	202
	129	145	137	137	144	136	165	171	162	167	187	190
Operating Profit	-4	-13	-3	-12	6	-3	-2	25	8	6	9	12
OPM %	-3%	-10%	-2%	-9%	4%	-2%	-1%	13%	5%	3%	5%	6%
	13	95	-2	25	8	24	40	33	12	10	5	15
Interest	10	4	5	3	3	4	3	2	3	6	5	4
Depreciation	5	17	4	2	2	3	2	2	3	4	4	4
Profit before tax	-6	62	-14	8	8	15	33	54	15	7	5	19
Tax %	13%	22%	34%	84%	48%	6%	10%	13%	25%	15%	-2%	4%
	-7	48	-18	1	4	14	29	47	11	6	5	18
EPS in Rs	-0.87	6.28	-2.38	0.17	0.55	1.83	3.83	6.16	1.49	0.74	0.64	2.32
Dividend Payout %	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%

Compounded Sales Growth
10 Years:	4%
5 Years:	4%
3 Years:	6%
TTM:	3%

Compounded Profit Growth
10 Years:	10%
5 Years:	10%
3 Years:	17%
TTM:	115%

Stock Price CAGR
10 Years:	17%
5 Years:	-5%
3 Years:	14%
1 Year:	-8%

Return on Equity
10 Years:	11%
5 Years:	12%
3 Years:	8%
Last Year:	12%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity Capital	77	77	77	77	77	77	77	77	77	77	77	77
Reserves	-86	-38	-51	-50	-46	-32	-3	43	54	60	63	82
	46	47	42	43	40	31	28	27	45	46	51	57
	132	94	93	128	144	111	108	84	70	67	79	66
Total Liabilities	169	180	160	197	214	186	210	231	246	250	270	281
	91	72	72	59	58	57	57	58	85	88	87	91
CWIP	1	9	3	14	24	0	1	12	4	0	0	2
Investments	1	8	5	5	9	18	27	33	32	29	32	32
	76	92	80	119	123	110	125	128	125	133	151	156
Total Assets	169	180	160	197	214	186	210	231	246	250	270	281

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	-8	-75	5	-7	19	-7	-2	11	6	9	-18	13
	10	80	-3	18	-9	17	10	5	-17	-5	13	-10
	-1	-3	-6	-2	-6	-14	-6	-19	9	-3	-2	-2
Net Cash Flow	1	2	-4	8	3	-4	2	-3	-2	1	-6	1
Free Cash Flow	1	12	1	8	9	-10	7	16	-15	6	-20	7
CFO/OP	90%	551%	-252%	-107%	453%	134%	22%	60%	120%	217%	-160%	114%

Ratios

Consolidated Figures in Rs. Crores / View Standalone

	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Debtor Days	74	83	79	100	84	79	87	52	59	55	82	86
Inventory Days	86	72	66	75	61	76	58	48	62	58	75	68
Days Payable	139	135	138	207	191	184	184	151	131	133	158	125
Cash Conversion Cycle	22	20	6	-32	-46	-29	-39	-50	-10	-19	-2	29
Working Capital Days	-318	-156	-185	-187	-190	-140	-88	-25	-43	-35	-25	13
ROCE %	-19%	-44%	-1%	-5%	16%	25%	18%	34%	11%	7%	9%	12%

Insights

In beta

Mar 2014

Mar 2015

Mar 2016

Mar 2017

Mar 2018

Mar 2019

Mar 2020

Mar 2021

Mar 2022

Mar 2023

Mar 2024

Mar 2025

Domestic Revenue (Geographical Segment)
₹ Lakhs

x,xxx.xx	x,xxx.xx	xx,xxx.xx	xx,xxx.xx	x,xxx.xx	xx,xxx.xx	x,xxx.xx	xx,xxx.xx	xx,xxx.xx	xx,xxx.xx	xx,xxx.xx	xx,xxx.xx
x,xxx.xx	x,xxx.xx	xx,xxx.xx	x,xxx.xx	x,xxx.xx	x,xxx.xx	x,xxx.xx	x,xxx.xx	x,xxx.xx	x,xxx.xx	x,xxx.xx	x,xxx.xx
					x	x	xx		xx		xx
				xx					xxx	xxx	xxx
		xxx	xx

Please log in to see hidden values.

Export Revenue (Geographical Segment)
₹ Lakhs

IVD Approved Molecular Tests (CoSara Diagnostics)
Number

Number of Internationally Registered Products (Asence Group)
Number

Number of New Product Registrations (Global)
Number

Extracted by Screener AI

Shareholding Pattern

Numbers in percentages

3 Recently

	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
	30.78%	30.78%	30.78%	30.78%	30.78%	31.35%	31.35%	31.35%	31.35%	31.35%	31.36%	31.36%
	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.38%	0.38%	0.34%	0.34%	0.00%
	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.10%	0.10%	0.00%	0.00%	0.00%	0.00%
	69.22%	69.23%	69.21%	69.23%	69.22%	68.65%	68.54%	68.18%	68.26%	68.32%	68.29%	68.64%
No. of Shareholders	1,77,743	1,75,222	1,71,944	1,70,079	1,69,228	1,72,338	1,71,221	1,70,912	1,69,630	1,70,015	1,68,396	1,67,599

	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	30.75%	30.75%	30.76%	30.76%	30.76%	30.76%	30.77%	30.78%	31.35%	31.36%
	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.38%	0.00%
	0.01%	0.01%	0.01%	0.01%	0.01%	0.01%	0.00%	0.00%	0.10%	0.00%
	69.25%	69.25%	69.24%	69.24%	69.24%	69.24%	69.22%	69.23%	68.18%	68.64%
No. of Shareholders	1,66,010	1,64,094	1,61,546	1,60,045	1,64,156	1,81,213	1,78,274	1,70,079	1,70,912	1,67,599

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

All

Ambalal Sarabhai Enterprises Ltd

Ambalal Sarabhai Enterprises Ltd

Peer comparison

Quarterly Results

Profit & Loss

Balance Sheet

Cash Flows

Ratios

Insights

Shareholding Pattern

Documents

Announcements

Annual reports